Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Leukogene Therapeutics Secures Strategic Funding From SCRA and SC Launch
Growth StageVenture Capital

Leukogene Therapeutics Secures Strategic Funding From SCRA and SC Launch

•November 12, 2025
•Nov 12, 2025
0

Participants

Leukogene

Leukogene

company

South Carolina Research Authority

South Carolina Research Authority

investor

Why It Matters

The infusion of public‑sector capital bolsters Leukogene’s ability to advance its pipeline, potentially accelerating the delivery of novel treatments for hard‑to‑treat cancers and enhancing South Carolina’s biotech ecosystem.

Deal Summary

Leukogene Therapeutics, a biopharmaceutical firm focused on next‑generation cancer therapies, announced it has received strategic funding from the South Carolina Research Authority and its affiliate SC Launch Inc. The financing, disclosed on November 12, 2025, aims to accelerate the company's development pipeline.

0

Comments

Want to join the conversation?

Loading comments...